Diagnostic Performance of Age-Volume Ratio versus Prostate-Specific Antigen Density for Prostate Cancer Detection in a Rural Chinese Biopsy Cohort: a Retrospective Study
This retrospective study of a rural Chinese cohort demonstrates that while Prostate-Specific Antigen Density (PSAD) remains the superior standalone predictor for prostate cancer, the Age-Volume Ratio (AVR) offers comparable performance in the PSA gray zone and, when used in a serial combination strategy with PSAD, significantly improves specificity to help reduce unnecessary biopsies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of men, the journey toward understanding prostate health begins with a simple blood test that measures a protein called prostate-specific antigen. When this protein appears in the blood, it signals that the prostate gland is active, but it does not automatically mean cancer is present. The gland can swell due to age or benign growths, causing the levels to rise and creating a difficult gray area for doctors. In this uncertain zone, where the numbers are elevated but not definitively high, physicians face a tough choice: proceed with a needle biopsy to look for cancer, or wait and watch. A biopsy is an invasive procedure, and performing it on men who do not have cancer causes unnecessary stress and physical discomfort. To help navigate this decision, doctors have long used a calculation called prostate-specific antigen density, which divides the blood level of the protein by the size of the prostate. The logic is that a smaller gland producing the same amount of protein is more suspicious than a large one. However, this method relies entirely on an accurate measurement of the gland's size, and it ignores a crucial factor: age. As men grow older, their risk of developing cancer naturally increases, a variable that the standard calculation overlooks.
Researchers in Shanghai recently set out to test a different approach in a group of men from a rural coastal region of China. They examined a new calculation called the age-volume ratio, which simply divides a man's age by the size of his prostate. This method attempts to capture both the shrinking of the gland and the passage of time in a single number. The team looked at the medical records of 111 men who had undergone prostate biopsies between 2023 and 2026. They compared how well the traditional density method and the new age-volume ratio performed at predicting whether these men actually had cancer. The study focused on the most common clinical dilemmas: men whose blood protein levels were in the middle range, and men whose density calculations were also in a middle, uncertain range.
The results showed that for the entire group of men, the traditional density method remained the strongest single tool for spotting cancer. It correctly identified the presence of the disease more often than the new age-volume ratio or the raw blood test alone. However, the story changed when the researchers looked at specific groups. In the group of men with blood protein levels in the middle gray zone, the new age-volume ratio performed just as well as the traditional density method. Both were far superior to looking at the blood level alone. Even more interesting was the finding in the group where the traditional density calculation was stuck in its own middle gray zone. In this difficult scenario, where the standard method struggled to distinguish between cancer and non-cancer, the age-volume ratio held its ground. It maintained a better ability to tell the difference, suggesting that adding the element of age helped compensate for the limitations of the size-based calculation.
The researchers also explored what happened when they used both methods together. They found that requiring a man to meet the criteria for both the new ratio and the traditional density before recommending a biopsy significantly reduced the number of false alarms. This combined approach meant that fewer men without cancer would undergo an unnecessary needle procedure, while still catching the vast majority of actual cases. The study did reveal a limitation, however. When the researchers focused only on the most aggressive forms of cancer, the new age-volume ratio became less effective than the traditional method. This suggests that while the new ratio is excellent for deciding who needs a biopsy in the first place, it is not the best tool for predicting how dangerous the cancer might be.
Ultimately, this work provides a clearer picture for doctors in similar communities. It confirms that while the traditional density calculation is still the best overall guide, the age-volume ratio is a powerful partner, especially when the standard numbers are ambiguous. By combining these two approaches, clinicians can make more precise decisions, sparing men from unnecessary procedures without missing the cancers that need treatment. The study highlights that in the complex landscape of prostate health, looking at both the size of the gland and the age of the patient offers a more complete view than either factor alone.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.